Renal Cell Carcinoma Histology and Risk Stratification

Experts on renal cell carcinoma describe the RCC histologies and tools used for risk stratification.

Related Videos
Experts on renal cell carcinoma
Expert on urothelial carcinoma
Matthew Galsky, MD
Virginia Kaklamani, MD, an expert on breast cancer
Jonathan Chatzkel, MD
David A. Braun, MD, PhD
Paul L. Nguyen, MD, senior physician, director, Genitourinary Clinical Center for Radiation Oncology, Dana-Farber Cancer Institute, professor of radiation oncology, Harvard Medical School,
Guru P. Sonpavde, MD, medical director, Genitourinary (GU) Oncology, assistant director, Clinical Research Unit, Christopher K. Glanz Chair, Bladder Cancer Research, AdventHealth Cancer Institute
Related Content

Pembrolizumab Data Highlight Potential for Adjuvant Immunotherapy in RCC

March 17th 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

March 15th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

March 13th 2023

Cabozantinib Plus Atezolizumab Produces Durable Responses in Non–Clear Cell RCC

March 10th 2023

Pembrolizumab Data Highlight Potential for Adjuvant Immunotherapy in RCC

March 17th 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

March 15th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

March 13th 2023

Cabozantinib Plus Atezolizumab Produces Durable Responses in Non–Clear Cell RCC

March 10th 2023

Pembrolizumab Data Highlight Potential for Adjuvant Immunotherapy in RCC

March 17th 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

February 16th 2023

SRK-181 Alone or With Anti–PD-(L)1 Therapy Elicits Early Efficacy in Select Solid Tumors

March 15th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

March 13th 2023

Cabozantinib Plus Atezolizumab Produces Durable Responses in Non–Clear Cell RCC

March 10th 2023